GT Biopharma, Inc. has undergone a transition in its executive leadership team, specifically in the role of Chief Financial Officer (CFO). On June 3, 2024, the employment of Manu Ohri as the CFO was terminated. Subsequently, on the same day, Alan L. Urban was appointed as the new CFO of the company.
Mr. Urban, aged 55, brings with him a wealth of experience, having served in various executive roles in finance and accounting across different industries. He has previously served as a member of the Board of Directors of GT Biopharma, Inc. from June 2022 to May 2023. His prior experience includes positions as CFO for SRAX, Inc., Creek Road Miners, Inc., and Research Solutions, Inc. He has also held significant roles in companies such as ReachLocal, Inc. and Infotrieve, Inc. Mr. Urban is a Certified Public Accountant (currently inactive) and holds a B.S. in Business with a concentration in Accounting Theory and Practice from California State University, Northridge.
This appointment comes amidst a broader restructuring of GT Biopharma’s executive management team. Dr. Gregory Berk, the current President of R&D and Chief Medical Officer, has been appointed as the interim Chief Executive Officer (CEO), while Michael Breen, a current Board member, has assumed the role of Executive Chairman of the Board. Additionally, Dr. Gavin Choy, the Chief Clinical Development Officer, has been appointed as the Acting CFO.
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutic products based on its proprietary Tri-specific natural killer (NK) cell engager, TriKE® platform. The company aims to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells.
The company expresses its appreciation to the outgoing executives for their dedicated service and strategic guidance. Dr. Gregory Berk, the interim CEO, expressed his commitment to leading the company during this crucial phase, highlighting the strong executive team and supportive Board as assets for advancing the company’s mission and goals.
This transition in leadership underscores GT Biopharma’s commitment to driving growth and advancing its innovative therapies towards commercialization and global partnerships in the field of immuno-oncology.
